Results Healthcare and Harel Consulting sign Cooperation Agreement to Facilitate Licensing in Emerging Markets
Results Healthcare, a healthcare advisory specialist that is part of the Results International Group, and Harel Consulting, a US-based business development consultancy with proprietary ties to leading pharmaceutical companies across the emerging markets, have signed a Cooperation Agreement.
According to the terms of the agreement, Results Healthcare will leverage its knowledge and relationships in the pharmaceutical and medical device sectors, particularly in Europe, to assist in identifying innovative companies that may become licensors for Harel Consulting’s Emerging Markets clients. Once the licensors are identified, the two companies may also work together to consummate the licensing deals.
Harel Consulting is led by Jacob Harel, a seasoned pharmaceutical executive with over 25 years of experience in the industry. Prior to founding Harel Consulting, he most recently served as Head of Corporate Business Development at Merck & Co., during which time he structured and negotiated a variety of deals around the globe and especially in Emerging Markets.
Kevin Bottomley, Managing Director at Results Healthcare commented on the agreement: “We are very pleased to have this opportunity to work with Harel Consulting. Jacob’s background enables him to see Emerging Markets opportunities from a developed world perspective. We believe that together we are well positioned to find the right opportunities for our clients in these markets.”
Jacob Harel, founder of Harel Consulting added: “Results Healthcare has an outstanding reputation for its knowledge and expertise in the pharmaceutical and medical devices sectors. Results Healthcare is well-suited to help us find, facilitate and execute licensing deals for our clients in Latin America, Eastern Europe, Middle East, Asia Pacific and Africa. We look forward to a fruitful collaboration.”
These future licensing deals are expected to bring more therapeutic choices to millions of patients in the Emerging Markets. Results Healthcare and Harel Consulting indicated that they are proud to make a contribution to the improvement of patients' health in these markets.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance